The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat is not yet available in India.

FDA approves Mitapivat, the first oral treatment for thalassemia anemia, helping reduce transfusion needs and raise ...

The FDA approved mitapivat (Aqvesme) as a disease-modifying treatment for anemia in adults with alpha- or beta-thalassemia, a rare inherited blood disease that affects hemoglobin production. An oral ...

Iron deficiency anemia (IDA) and thalassemia represent two of the most prevalent causes of microcytic anemia worldwide. Effective screening is critical not only to guide appropriate treatment — as IDA ...

The US Food and Drug Administrations (FDA) approval of the first-ever oral pill for anaemia in adults with thalassemia marks a historic milestone and can be a game changer in the management of the ...

Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ...

Investigators used MRI to evaluate brain perfusion in patients with transfusion-dependent (n=54) and non–transfusion-dependent (n=23) β-thalassemia versus 56 controls. They found that relative ...

The US FDA has approved Mitapivat (Aqvesme), the first oral therapy for anemia in adults with alpha or beta thalassemia, ...

CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...

It is concerning that many people have experienced problems with haemoglobin due to haemoglobinopathies (genetically altered and/or synthesised mutations), and that most hemoglobinopathies are missed ...

U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat ...

Mitapivat is the first FDA-approved oral therapy for anaemia in all forms of thalassemia Reduced transfusion dependence may ...